Inflammatory factors play an important role in the process of fracture healing. The influence of interleukin (IL)1β, a key inflammatory factory, on new bone formation has been controversial. The aim of the present study was to investigate whether IL1β affects the osteogenic
differentiation of mouse bone marrow mesenchymal stem cells (MBMMSCs), and examined its effective concentration range and molecular mechanism of action. MBMMSC proliferation in the presence of IL1β was observed using a CellCounting Kit8 assay, and the effect of IL1β on MBMMSC
apoptosis was examined via flow cytometry. Alkaline phosphatase assay, Alizarin Red staining and quantitative assays were performed to evaluate the osteogenic differentiation of MBMMSCs. The expression levels of osteogenic differentiation markers were detected using reverse transcriptionquantitative
PCR (RTqPCR). It was demonstrated that within a concentration range of 0.011 ng/ml, IL1β promoted osteogenic differentiation of MBMMSCs and did not induce apoptosis. Furthermore, RTqPCR results indicated that IL1β increased osteogenic gene expression within this concentration
range. Moreover, Western blotting results identified that the bone morphogenetic protein/Smad (BMP/Smad) signaling pathway was significantly activated by IL1β under osteogenic conditions. Therefore, the present results suggested that within a certain concentration range, IL1β
promoted osteogenic differentiation and function of MBMMSCs via the BMP/Smad signaling pathway.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Orthopedics, Huainan First People's Hospital, Anhui University of Science and Technology, Huainan, Anhui 232000, P.R. China
Department of Orthopedics, Hefei First People's Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites